{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:25:22Z","timestamp":1769556322306,"version":"3.49.0"},"reference-count":56,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IRCCS Centro Neurolesi Bonino Pulejo","award":["Current research funds 2020"],"award-info":[{"award-number":["Current research funds 2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Liver fibrosis is defined as excessive extracellular matrix deposition in the hepatic parenchyma as a consequence of complex interactions among matrix-producing hepatic stellate cells (HSCs) and liver-resident and infiltrating cells. In addition to the liver, the process of fibrosis may represent end-stage disease of several diseases including kidneys, lungs, spleens, heart, muscles and at certain extent, the central nervous system and the peripheral nerves. To date, antifibrotic treatment of fibrosis represents an unconquered area for drug development. The aim of the present study was to test the efficacy of a new drug combination for the treatment of hepatic fibrosis in order to provide a proof-of-concept for the use of therapeutic agents in clinical practice. For this purpose, we have studied the effects of the PDGF inhibitor imatinib and the angiogenesis inhibitor sorafenib, administered alone or in combination, in reducing the progression of the fibrogenetic process in a pre-clinical model of liver damage induced in mice by repeated administration of Concanavalin A (ConA), resembling long-tern autoimmune hepatitis. Our results suggest that treatments with imatinib and sorafenib can modulate potently and, in a superimposable fashion, the fibrinogenic process when administered alone. However, and in agreement with the computational data presently generated, they only exert partial overlapping antifibrotic effects in modulating the main pathways involved in the process of liver fibrosis, without significant additive or synergist effects, when administered in combination.<\/jats:p>","DOI":"10.3390\/molecules25184310","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T21:20:28Z","timestamp":1600636828000},"page":"4310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-551X","authenticated-orcid":false,"given":"Antonio","family":"Pesce","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technology G.F. Ingrassia, University of Catania, Via Santa Sofia 86, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Ciurleo","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino Pulejo, C.da Casazza, 98124 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Bramanti","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino Pulejo, C.da Casazza, 98124 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana Concetta","family":"Armeli Iapichino","sequence":"additional","affiliation":[{"name":"Valdese Hospital, Via Silvio Pellico 19, 10125 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Petralia","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano Giuseppe","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technology G.F. Ingrassia, University of Catania, Via Santa Sofia 86, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-1992","authenticated-orcid":false,"given":"Paolo","family":"Fagone","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino Pulejo, C.da Casazza, 98124 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-8462","authenticated-orcid":false,"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-4620","authenticated-orcid":false,"given":"Katia","family":"Mangano","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.7150\/thno.47826","article-title":"Self-eating: Friend or foe? The emerging role of autophagy in fibrotic diseases","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yexcr.2018.06.002","article-title":"MicroRNA-21a-5p promotes fibrosis in spinal fibroblasts after mechanical trauma","volume":"370","author":"Wang","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.molmed.2018.04.007","article-title":"To Scar or Not to Scar","volume":"24","author":"Narang","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-\u03b2 as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J. Cell. Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/egh.11.92","article-title":"Update on hepatic stellate cells: Pathogenic role in liver fibrosis and novel isolation techniques","volume":"6","author":"Tacke","year":"2012","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1755-1536-6-19","article-title":"Experimental liver fibrosis research: Update on animal models, legal issues and translational aspects","volume":"6","author":"Liedtke","year":"2013","journal-title":"Fibrogenes. Tissue Repair"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00204-015-1543-4","article-title":"Experimental models of liver fibrosis","volume":"90","author":"Cogliati","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104694","DOI":"10.1016\/j.phrs.2020.104694","article-title":"Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence","volume":"155","author":"Aimo","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2019.00056","article-title":"Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case Series","volume":"8","author":"Philips","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jcp.31.5.395","article-title":"The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization","volume":"31","author":"Anthony","year":"1978","journal-title":"J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Friedman","year":"2011","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","article-title":"Emerging therapeutic targets for the treatment of hepatic fibrosis","volume":"21","author":"Fagone","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/ijmm.2015.2264","article-title":"Identification of novel targets for the diagnosis and treatment of liver fibrosis","volume":"36","author":"Fagone","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1477-2574.2012.00465.x","article-title":"Does transient elastography (FibroScan\u00ae) have a role in decision making in hepatocellular carcinoma?","volume":"14","author":"Pesce","year":"2012","journal-title":"HPB"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.dld.2004.11.009","article-title":"Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation","volume":"37","author":"Carpino","year":"2005","journal-title":"Dig. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: From physiopathology to therapy","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kagan, P., Sultan, M., Tachlytski, I., Safran, M., and Ben-Ari, Z. (2017). Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176173"},{"key":"ref_21","first-page":"4838","article-title":"Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis","volume":"15","author":"Lu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11605-011-1764-7","article-title":"Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL 4-Treated Mice","volume":"16","author":"Kuo","year":"2012","journal-title":"J. Gastrointest. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejphar.2011.08.041","article-title":"Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis","volume":"670","author":"Shaker","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2005.06.015","article-title":"Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term","volume":"44","author":"Neef","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_26","first-page":"899","article-title":"Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-\u03b2 with a combination of imatinib mesylate and ACE inhibitor in rats","volume":"17","author":"Yoshiji","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1478-3231.2012.02806.x","article-title":"Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Westra, I.M., Oosterhuis, D., Groothuis, G.M.M., and Olinga, P. (2014). The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095462"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2017.09.035","article-title":"Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis","volume":"266","author":"Shalaby","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","article-title":"STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib","volume":"46","author":"Deng","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yang, L., Ao, Q., Zhong, Q., Li, W., and Li, W. (2020). SIRT1\/IGFBPrP1\/TGF \u03b21 axis involved in cucurbitacin B ameliorating concanavalin A-induced mice liver fibrosis. Basic Clin. Pharmacol. Toxicol.","DOI":"10.1111\/bcpt.13446"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"116982","DOI":"10.1016\/j.lfs.2019.116982","article-title":"Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice","volume":"239","author":"Salah","year":"2019","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.2010.04303.x","article-title":"Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1","volume":"163","author":"Fagone","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2249.2011.04491.x","article-title":"Therapeutic potential of carbon monoxide in multiple sclerosis","volume":"167","author":"Fagone","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cavalli, E., Mazzon, E., Basile, M.S., Mangano, K., Di Marco, R., Bramanti, P., Nicoletti, F., Fagone, P., and Petralia, M.C. (2019). Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis. Medicina (Buenos Aires), 55.","DOI":"10.3390\/medicina55100667"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1593\/neo.10856","article-title":"Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells","volume":"12","author":"Rothweiler","year":"2010","journal-title":"Neoplasia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.drudis.2011.05.008","article-title":"mTOR as a multifunctional therapeutic target in HIV infection","volume":"16","author":"Nicoletti","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11332-018-0458-x","article-title":"Memory, personality and blood lactate during a judo competition","volume":"14","author":"Coco","year":"2018","journal-title":"Sport Sci. Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11332-018-0431-8","article-title":"The rise of lactic acid, from a pharmacist\u2019s laboratory to entry into the central nervous system","volume":"14","author":"Petralia","year":"2018","journal-title":"Sport Sci. Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jad.2019.11.127","article-title":"Pathogenic contribution of the Macrophage migration inhibitory factor family to major depressive disorder and emerging tailored therapeutic approaches","volume":"263","author":"Petralia","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102504","DOI":"10.1016\/j.autrev.2020.102504","article-title":"The cytokine network in the pathogenesis of major depressive disorder. Close to translation?","volume":"19","author":"Petralia","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-3083.2010.02451.x","article-title":"Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents","volume":"72","author":"Donia","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/imm.12267","article-title":"VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus","volume":"142","author":"Fagone","year":"2014","journal-title":"Immunology"},{"key":"ref_44","first-page":"2881","article-title":"Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma","volume":"16","author":"Presti","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44564","DOI":"10.1038\/srep44564","article-title":"Identification of novel chemotherapeutic strategies for metastatic uveal melanoma","volume":"7","author":"Fagone","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Basile, M.S., Mazzon, E., Russo, A., Mammana, S., Longo, A., Bonfiglio, V., Fallico, M., Caltabiano, R., Fagone, P., and Nicoletti, F. (2019). Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210276"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17951","DOI":"10.18632\/oncotarget.24885","article-title":"Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach","volume":"9","author":"Mangano","year":"2018","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.21873\/anticanres.11080","article-title":"Immunological and clinical impact of cancer stem cells in vulvar cancer: Role of cd133\/cd24\/abcg2-expressing cells","volume":"36","author":"Napoletano","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00262-018-2146-8","article-title":"Cancer immunotherapy in patients with brain metastases","volume":"67","author":"Caponnetto","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Basile, M.S., Fagone, P., Mangano, K., Mammana, S., Magro, G., Salvatorelli, L., Li Destri, G., La Greca, G., Nicoletti, F., and Puleo, S. (2019). KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. Cancers, 11.","DOI":"10.3390\/cancers11020245"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bone.2014.01.005","article-title":"Determination of chitinases family during osteoclastogenesis","volume":"61","author":"Tibullo","year":"2014","journal-title":"Bone"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/jnr.21660","article-title":"A cytoprotective role for the heme oxygenase-1\/CO pathway during neural differentiation of human mesenchymal stem cells","volume":"86","author":"Barbagallo","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cels.2017.11.001","article-title":"The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations","volume":"6","author":"Keenan","year":"2018","journal-title":"Cell Syst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.mcn.2017.10.001","article-title":"CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients","volume":"85","author":"Sanfilippo","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chang, L.C., Lin, H.M., Sibille, E., and Tseng, G.C. (2013). Meta-analysis methods for combining multiple expression profiles: Comparisons, statistical characterization and an application guideline. BMC Bioinformatics, 14.","DOI":"10.1186\/1471-2105-14-368"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:11:44Z","timestamp":1760177504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,20]]},"references-count":56,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["molecules25184310"],"URL":"https:\/\/doi.org\/10.3390\/molecules25184310","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,20]]}}}